Alto Neuroscience (ANRO) Accounts Payables (2023 - 2026)

Alto Neuroscience has disclosed Accounts Payables across 4 years of filings, most recently posting $3.4 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.4 million, up 143.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (up 143.42% YoY), and the FY2025 annual result was $1.9 million, up 18.94% from the prior year.
• Accounts Payables came in at $3.4 million for Q1 2026 at Alto Neuroscience, up from $1.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.4 million in Q1 2026 to a low of $1.1 million in Q4 2023.
• The 4-year median for Accounts Payables is $1.9 million (2024), against an average of $2.0 million.
• Across the five-year window, Accounts Payables plunged 42.62% in 2025 and soared 143.42% in 2026, its largest moves.
• Alto Neuroscience's Accounts Payables stood at $1.1 million in 2023, then surged by 47.02% to $1.6 million in 2024, then rose by 18.94% to $1.9 million in 2025, then soared by 79.39% to $3.4 million in 2026.
• The last three Accounts Payables figures came in at $3.4 million (Q1 2026), $1.9 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.